Miraca Holdings subsidiary Fujirebio Diagnostics' Lumipulse G β-Amyloid Ratio quantitative in vitro diagnostic test for Alzheimer's disease has been granted breakthrough device status by the FDA.
FDA accelerates review of Fujirebio's Alzheimer's test
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.